Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.36 |
| ▸ | DRD3 | P35462 | 6/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16357229 | 0.90 | HSD11B1 (0.34) | DRD2DRD3DRD4CHRM1PGR | |
| SCHEMBL17657225 | 0.87 | DRD2 (0.33) | DRD2DRD3DRD4CHRM1DRD1 | |
| SCHEMBL17657218 | 0.80 | ALDH1A1 (0.45) | PGRALOX15KDM4EALDH1A1 | |
| SCHEMBL15019768 | 0.79 | PGR (0.35) | PGRALOX15KDM4EALDH1A1 | |
| SCHEMBL18624648 | 0.76 | DRD2 (0.33) | DRD2DRD3DRD4CHRM1DRD1 | |
| SCHEMBL12723264 | 0.75 | PGR (0.44) | PGRKDM4EALDH1A1 | |
| SCHEMBL31913 | 0.75 | PGR (0.49) | PGRKDM4EALDH1A1 | |
| SCHEMBL29388768 | 0.75 | PGR (0.49) | PGRKDM4EALDH1A1 | |
| SCHEMBL11978700 | 0.74 | PGR (0.41) | PGRKDM4EALDH1A1 | |
| SCHEMBL12109311 | 0.74 | PGR (0.41) | PGRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9893295-B2 | Compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-13 | — | — | US | disclosed |
| US-20160099421-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-07 | — | — | US | disclosed |
| US-20160099421-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160099421-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1B1, CRY2 | DRD2 956/4885DRD3 1043/4885DRD4 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.